Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, Annesi D, Queirolo P, Testori A, Ridolfi R, Parmiani G, Maio M. Di Giacomo AM, et al. Among authors: rivoltini l. Lancet Oncol. 2012 Sep;13(9):879-86. doi: 10.1016/S1470-2045(12)70324-8. Epub 2012 Aug 13. Lancet Oncol. 2012. PMID: 22894884 Clinical Trial.
Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study.
Belli F, Arienti F, Rivoltini L, Santinami M, Mascheroni L, Prada A, Ammatuna M, Marchesi E, Parmiani G, Cascinelli N, et al. Belli F, et al. Among authors: rivoltini l. Melanoma Res. 1992 Nov;2(4):263-71. doi: 10.1097/00008390-199211000-00007. Melanoma Res. 1992. PMID: 1490114
Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.
Arienti F, Gambacorti-Passerini C, Borin L, Rivoltini L, Orazi A, Pogliani EM, Corneo G, Parmiani G. Arienti F, et al. Among authors: rivoltini l. Ann Oncol. 1992 Feb;3(2):155-62. doi: 10.1093/oxfordjournals.annonc.a058133. Ann Oncol. 1992. PMID: 1606087 Free article.
Biologic agents as modifiers of chemotherapeutic effects.
Parmiani G, Rivoltini L. Parmiani G, et al. Among authors: rivoltini l. Curr Opin Oncol. 1991 Dec;3(6):1078-86. doi: 10.1097/00001622-199112000-00017. Curr Opin Oncol. 1991. PMID: 1843110 Review.
240 results